Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F11%3A43870423" target="_blank" >RIV/62157124:16370/11:43870423 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.3109/03639045.2011.560156" target="_blank" >http://dx.doi.org/10.3109/03639045.2011.560156</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/03639045.2011.560156" target="_blank" >10.3109/03639045.2011.560156</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease

Popis výsledku v původním jazyce

Background: In recent years, many achievements have been realized in the therapy of inflammatory bowel disease (IBD) although its etiology remains unknown. Thus IBD treatment is symptomatic and targets general inflammatory mechanisms. Oral formulations containing 5-aminosalicylic acid (5-ASA) have become the standard therapy for mild-to-moderate IBD. Objective: This article is a review of recently published research dealing with new 5-ASA dosage forms. Thus promising candidates for IBD treatment evaluated in vitro are reported; systems tested in vivo in trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats are mentioned; and 5-ASA formulations used in clinical studies are presented. Moreover, all oral dosage forms containing 5-ASA or its prodrugs are reviewed; their characteristics and utilization in IBD treatment are discussed. Conclusion: In several clinical studies, it has been shown that multiparticulates such as pellets offer more advantages as compared with single unit for

Název v anglickém jazyce

Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease

Popis výsledku anglicky

Background: In recent years, many achievements have been realized in the therapy of inflammatory bowel disease (IBD) although its etiology remains unknown. Thus IBD treatment is symptomatic and targets general inflammatory mechanisms. Oral formulations containing 5-aminosalicylic acid (5-ASA) have become the standard therapy for mild-to-moderate IBD. Objective: This article is a review of recently published research dealing with new 5-ASA dosage forms. Thus promising candidates for IBD treatment evaluated in vitro are reported; systems tested in vivo in trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats are mentioned; and 5-ASA formulations used in clinical studies are presented. Moreover, all oral dosage forms containing 5-ASA or its prodrugs are reviewed; their characteristics and utilization in IBD treatment are discussed. Conclusion: In several clinical studies, it has been shown that multiparticulates such as pellets offer more advantages as compared with single unit for

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Drug Development and Industrial Pharmacy

ISSN

0363-9045

e-ISSN

—

Svazek periodika

37

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

1100-1109

Kód UT WoS článku

000293543700012

EID výsledku v databázi Scopus

—